Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Glaukos Corporation is a medical instruments & supplies business based in the US. Glaukos Corporation shares (GKOS) are listed on the NYSE and all prices are listed in US Dollars. Glaukos Corporation employs 653 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$46.27|
|52-week range||$44.37 - $99.00|
|50-day moving average||$51.35|
|200-day moving average||$67.14|
|Wall St. target price||$50.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.33|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||3.24%|
|1 month (2021-09-22)||-9.72%|
|3 months (2021-07-22)||-7.46%|
|6 months (2021-04-22)||-49.57%|
|1 year (2020-10-21)||-17.38%|
|2 years (2019-10-21)||-26.79%|
|3 years (2018-10-19)||60|
|5 years (2016-10-21)||32.65%|
Valuing Glaukos Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Glaukos Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Glaukos Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.64. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Glaukos Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$284.1 million|
|Gross profit TTM||$158 million|
|Return on assets TTM||-2.41%|
|Return on equity TTM||-9.68%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
There are currently 2.0 million Glaukos Corporation shares held short by investors – that's known as Glaukos Corporation's "short interest". This figure is 14.1% down from 2.3 million last month.
There are a few different ways that this level of interest in shorting Glaukos Corporation shares can be evaluated.
Glaukos Corporation's "short interest ratio" (SIR) is the quantity of Glaukos Corporation shares currently shorted divided by the average quantity of Glaukos Corporation shares traded daily (recently around 608101.54320988). Glaukos Corporation's SIR currently stands at 3.24. In other words for every 100,000 Glaukos Corporation shares traded daily on the market, roughly 3240 shares are currently held short.
However Glaukos Corporation's short interest can also be evaluated against the total number of Glaukos Corporation shares, or, against the total number of tradable Glaukos Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Glaukos Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Glaukos Corporation shares in existence, roughly 40 shares are currently held short) or 0.044% of the tradable shares (for every 100,000 tradable Glaukos Corporation shares, roughly 44 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Glaukos Corporation.
Find out more about how you can short Glaukos Corporation stock.
We're not expecting Glaukos Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Glaukos Corporation's shares have ranged in value from as little as $44.37 up to $99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Glaukos Corporation's is 1.7635. This would suggest that Glaukos Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California. .
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.